

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner



Maine Department of Health and Human Services
Maine Center for Disease Control and Prevention
11 State House Station
286 Water Street
Augusta, Maine 04333-0011
Tel; (207) 287-8016; Fax (207) 287-9058
TTY: Dial 711 (Maine Relay)

To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: NEW Vaccine Presentations – Prevnar 20 and Menveo
Date: August 28, 2023

The Maine Immunization Program is pleased to announce two new vaccine presentations, Pfizer's Prevnar 20 and GSK's Menveo. Both vaccines have been approved by the U.S. FDA and CDC's Advisory Committee on Immunization Practices (ACIP) and will be available in ImmPact to order starting September 1, 2023.

PREVNAR 20 (PCV20) – Pneumococcal 20-valent Conjugate Vaccine

ACIP recommended the use of either pneumococcal conjugate vaccines (PCV) PCV15 or PCV20, to be given to all children aged 2–23 months according to currently recommended [PCV dosing and schedules](#). Prevnar 20 is recommended to be administered as a 4-dose series at 2, 4, 6, and 12 through 15 months of age (and at least 2 months after the third dose). Prevnar 20 is given intramuscular and supplied as 0.5mL single-dose pre-filled syringe.

MENVEO - Meningococcal (Groups A, C, Y, and W)

Menveo vaccine now has two presentations (1-vial and 2-vial), indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W. The [Prescribing Information describes two presentations of Menveo](#); the current two-vial presentation and a **new one-vial presentation**.

A summary of the two presentations is described below:

Menveo two-vial presentation

- For use in individuals 2 months through 55 years of age
- The two-vial presentation includes a vial with a gray cap containing the MenCYW-135 liquid conjugate component and a vial with an orange cap containing the MenA lyophilized conjugate component.
 - The contents of the vials must be combined to form MENVEO prior to administration.

Menveo one-vial presentation – NEW

- For use in individuals 10 years through 55 years of age.
- The one-vial presentation contains MENVEO in a single vial with a pink cap
- This presentation does NOT require reconstitution.

- Use EITHER presentation for individuals 10 years through 55 years of age.
- Use ONLY the two-vial presentation for individuals at high risk, 2 months through 9 years of age.

IMPORTANT DIFFERENCES BETWEEN PRESENTATIONS



MENVEO 1-vial presentation

- Approved for use in individuals aged **10 through 55 years**¹
- Safety and effectiveness in children aged younger than 10 years have not been established
- Supplied in a single-dose vial with a pink cap and does not require reconstitution
- NDC numbers:
 - 10 vials NDC 58160-827-03
 - Outer carton NDC 58160-827-30



MENVEO 2-vial presentation

- Approved for use in individuals aged **2 months through 55 years** of age¹
- Supplied as a vial with an orange cap containing the MenA lyophilized conjugate component and a vial with a gray cap containing the MenCYW-135 liquid conjugate component
- The lyophilized conjugate component and the liquid conjugate component must be combined before use to form a single dose of MENVEO
- NDC numbers remain the same:
 - Five vials containing MenA lyophilized conjugate component NDC 58160-958-01
 - Five vials containing MenCYW-135 liquid conjugate component NDC 58160-959-01
 - Outer carton NDC 58160-955-09

Vaccination may not protect all recipients.

[MENVEO Vial Presentations](#)

If you have any questions, please contact the Maine Immunization Program at (207) 287-3746 or email ImmunizeME.DHHS@maine.gov.